目的:探讨穿虎祛痛合剂联合秋水仙碱治疗难治性痛风合并多种并发症的疗效。方法:报告1例长期应用激素治疗难治性痛风后导致多种并发症的患者应用穿虎祛痛合剂联合秋水仙碱治疗的临床资料。结果:在停用激素后,应用穿虎祛痛合剂联合小剂量秋水仙碱治疗后,患者双踝关节疼痛显著减轻,关节肿痛也没有加重的现象,痛风发作频率明显减少,尿酸下降,血糖控制良好且蛋白尿转阴,无胸闷憋气等冠心病症状,并未再发生骨质疏松骨折及下肢血栓。结论:难治性痛风患者给予穿虎祛痛合剂联合秋水仙碱治疗可减少激素治疗带来的各种并发症,为难治性痛风合并多种并发疾病提供新思路。Objective: To evaluate the efficacy of Chuanhu Qutong mixture in conjunction with colchicine for the treatment of refractory gout accompanied by multiple complications. Methods: This article presents the clinical data from a case study involving the use of Chuanhu Qutong mixture in conjunction with colchicine for managing multiple complications arising from prolonged glucocorticoid therapy in a patient with refractory gout. Results: Following the discontinuation of glucocorticoids, the patient received Chuanhu Qutong mixture combined with a low dose of colchicine. Significant relief was observed in bilateral ankle joint pain, with no exacerbation of joint swelling or pain. The frequency of gout attacks markedly decreased, serum uric acid levels declined, blood glucose was well controlled, proteinuria became negative, and there were no recurrent symptoms of coronary heart disease such as chest tightness or breathlessness, osteoporosis fractures, or lower extremity thrombosis. Conclusion: The combination of Chuanhu Qutong mixture and colchicine can mitigate complications associated with glucocorticoid therapy in patients with refractory gout and provide new therapeutic insights for managing this condition with multiple concurrent diseases.
目的:克罗恩病和痛风发病率逐年增高,但其关联性尚未明确。本研究利用孟德尔随机化方法,探讨克罗恩病与痛风之间的潜在因果关系。方法:我们选取与克罗恩病和痛风显著关联的单核苷酸多态性作为工具变量,利用公开的全基因组关联研究的汇总统计数据进行分析。我们采用多种MR方法并进行了敏感性分析。结果:克罗恩病与痛风的发病风险正相关(OR = 1.00060493,95%置信区间1.00013013~1.00107996,P值 = 0.01251316)。敏感性分析进一步印证了该发现,未见明显的异质性和水平多效性。结论:我们的研究结果表明克罗恩病与痛风之间存在正相关关系。这一发现为克罗恩病与痛风之间的关系及其病理生理机制提供了新的见解,并为痛风的预防和治疗提出了新策略。Objective: The incidence of Crohn’s disease and gout is increasing year by year, but the correlation is not clear, so we conducted a two-sample bidirectional mendelian randomization study to examine the association between them. Method: We selected single nucleotide polymorphisms significantly associated with Crohn’s disease and gout as instrumental variables and analyzed them using summary statistics from publicly available genome-wide association studies. We used multiple MR methods and performed sensitivity analyses. Results: The results revealed that Crohn’s disease was positively associated with the risk of developing gout (Odds Ratio, OR = 1.00060493, 95% Confidence Interval, CI, 1.00013013~1.00107996, P value = 0.01251316). Sensitivity analyses further corroborated the finding, with no significant heterogeneity or horizontal pleiotropy seen. Conclusions: Our findings suggest a positive association between Crohn’s disease and gout. This finding provides new insights into the relationship between Crohn’s disease and gout and its pathophysiologic mechanisms, and new strategies for the prevention and treatment of gout.